Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive (HR+), HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT05384119
What this trial is testing

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Tvardi Therapeutics, Incorporated 6
Testing effectiveness (Phase 2)Study completedNCT05549505
What this trial is testing

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Who this might be right for
Breast Cancer
Arvinas Inc. 152
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Not applicableLooking for participantsNCT06930859
What this trial is testing

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,766
Testing effectiveness (Phase 2)Study completedNCT03007992
What this trial is testing

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Johannes Gutenberg University Mainz 9
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Not applicableLooking for participantsNCT07546695
What this trial is testing

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Who this might be right for
Breast Cancer
University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Not applicableStudy completedNCT05709158
What this trial is testing

Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Who this might be right for
Breast Cancer
Pfizer 4,184
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Large-scale testing (Phase 3)Study completedNCT05375461
What this trial is testing

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Who this might be right for
HR-positive,HER2-negative in Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293
Large-scale testing (Phase 3)Study completedNCT03462251
What this trial is testing

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Who this might be right for
Breast CancerHormone Receptor Positive TumorHER 2 Negative Breast Cancer
iOMEDICO AG 41
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Large-scale testing (Phase 3)Looking for participantsNCT07190443
What this trial is testing

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Who this might be right for
Breast CancerLocoregional RecurrenceAbemaciclib+1 more
Japanese Foundation for Cancer Research 290
Next Page